Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Rockwell Medical Inc (RMTI)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
$7.60-5.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RMTI yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Adjusted EBITDA between $1M and $2M in 2026 | Adjusted EBITDA is expected between $1 million and $2 million. | Intact | Adjusted EBITDA falls below $1 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk turnaround-style business, not a proven durable compounder: it remains loss-making, and recent financial performance is neutral and below its industry cohort. The multi-year view is in a watch state, with some operating progress but no fresh break in the thesis.
The valuation model describes RMTI as cheap versus peers, but confidence in that reading is low. Its negative expectations gap suggests the market’s assumptions are cautious, while the model also indicates a premium versus peers, making the overall valuation signal mixed.
Near term, an elevated risk of another earnings miss matters, given the smaller company size and consecutive misses; guidance was reaffirmed on August 13, 2026. Over the multi-year view, cash flow, gross margin, and adjusted EBITDA have improved, but the 2026 goals remain unproven, and the company is still loss-making.
The key test is whether RMTI delivers positive operating cash flow and reaches its stated 2026 margin and adjusted EBITDA goals. A guidance cut or further weakening in jobs data would add pressure, while continued strength among healthcare peers could support sector momentum.
The 1-to-3-year read is a fragile operating-progress story: improving cash flow and margins are encouraging, but losses, repeated earnings misses, and high risk keep the thesis dependent on execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company targets a gross margin near 20%. |
| Improving |
| Gross margin falls below 18% in FY26 |
Gross margin: 18.24% FY2026-Q2; GAAP. Published target: 18%-22%. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202618.239595 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve positive operating cash flow in 2026 | Management plans to achieve positive operating cash flow by year-end. | Improving | Operating cash flow remains negative through FY26 | Cash from operations: $2.08M FY2026-Q2; GAAP. Published target: positive operating cash flow. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 20262,080,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches ~$72.5 million in FY26 | A primary condition in Rockwell Medical Inc's published investment case. The stated target is ~$72.5 million. | Intact | Revenue falls below $70 million in FY26 | Revenue: $17.78M FY2026-Q2; GAAP. Published target: ~$72.5 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202617,780,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.09 → $-0.20 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-25 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-26 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-27 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-28 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-29 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-07-30 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-07-31 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-01 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-02 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-03 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-04 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-05 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-06 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-08 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-09 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-10 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-12 | $-0.09 | $78,290,000 | 2 / 2 |
| 2026-08-13 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-14 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-15 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-16 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-17 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-18 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-19 | $-0.09 | $78,305,500 | 1 / 1 |
| 2026-08-20 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-21 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-22 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-23 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-24 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-25 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-26 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-27 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-28 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-29 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-30 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-08-31 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-01 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-02 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-03 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-04 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-05 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-06 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-07 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-08 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-09 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-10 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-11 | $-0.17 | $78,305,500 | 1 / 1 |
| 2026-09-12 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-13 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-14 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-15 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-16 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-17 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-18 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-19 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-20 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-21 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-22 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-23 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-24 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-25 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-26 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-27 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-28 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-29 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-09-30 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-01 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-02 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-03 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-04 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-05 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-06 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-07 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-08 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-09 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-10 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-11 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-12 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-13 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-14 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-15 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-16 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-17 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-18 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-19 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-20 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-21 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-22 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-23 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-24 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-25 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-26 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-27 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-28 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-29 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-30 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-10-31 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-11-01 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-11-02 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-11-03 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-11-04 | $-0.20 | $78,153,500 | 1 / 1 |
| 2026-11-05 | $-0.20 | $78,153,500 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.